title: Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
abstract: Valspodar is a cyclosporine D analog used as a chemotherapy adjunct for modifying multidrug resistance. Two studies were sequentially performed to select an optimal oral formulation and to characterize selected aspects of its clinical pharmacokinetics/dynamics. An initial four-way crossover study with 20 volunteers compared the pharmacokinetics of single fasting administrations of 200 mg by intravenous infusion and 600 mg orally as a conventional oral solution, a microemulsion oral solution, and a microemulsion soft gelatin capsule. The two microemulsion dosage forms demonstrated significantly faster and less variable rates of absorption compared with the conventional oral solution. The microemulsion dosage forms were bioequivalent with absolute bioavailability nearly double that of the conventional oral solution. Based on these results, the microemulsion capsule was further investigated in a four-way randomized crossover study with 24 volunteers who received single fasting administrations of 200, 400, and 600 mg and a 400-mg administration after a fat-rich meal. Dose proportionality in area under the curve (AUC) was demonstrated over this dose range. Administration after a fat-rich meal caused a slight time lag until absorption began, a delay in time to reach the peak concentration, and a moderate increase of 24% in AUC. Serial determinations of total bilirubin were explored as a potential pharmacodynamic marker for P-glycoprotein inhibition. A similar magnitude of reversible hyperbilirubinemia was seen at all dose levels suggesting that P-glycoprotein inhibition in the biliary canaliculi was maximal even at the lowest dose tested. The microemulsion formulation (oral solution or soft gelatin capsule) represents an improved and less variable oral delivery form providing dose-proportional drug exposure over a clinically relevant dose range.
authors.affiliation: Novartis Pharma Inc, Basel, Switzerland.
authors.forename: E A
authors.initials: EA
authors.lastname: Mueller
authors.forename: J M
authors.initials: JM
authors.lastname: Kovarik
authors.forename: Y
authors.initials: Y
authors.lastname: Uresin
authors.forename: S S
authors.initials: SS
authors.lastname: Preisig-Flückiger
authors.forename: S
authors.initials: S
authors.lastname: Hensel
authors.forename: P W
authors.initials: PW
authors.lastname: Lücker
authors.forename: B
authors.initials: B
authors.lastname: Holt
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000284:Administration, Oral; D019540:Area Under Curve; D001663:Bilirubin / Q000378:metabolism*; D018592:Cross-Over Studies; D003524:Cyclosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004041:Dietary Fats / Q000009:adverse effects*; D018565:Food-Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D003524:Cyclosporins; D004041:Dietary Fats; D007166:Immunosuppressive Agents; C070272:valspodar; D001663:Bilirubin